Novo Nordisk has released preliminary results from its phase 3 trials, known as evoke and evoke+, focusing on early-stage symptomatic Alzheimer’s disease. Conducted in Bagsværd, Denmark, these trials involved a total of 3,808 adult participants over two years.
Novo Nordisk’s Phase 3 Trials Findings
The trials aimed to assess the efficacy and safety of oral semaglutide in comparison to a placebo. Despite expectations, the results showed no significant differences in slowing the progression of Alzheimer’s disease, as indicated by the change in Clinical Dementia Rating – Sum of Boxes (CDR-SB) score from baseline.
Trial Overview
- Total Participants: 3,808 adults aged 55-85
- Duration: Two years
- Design: Randomized, double-blind, placebo-controlled
- Key Measure: Change in CDR-SB score
Although semaglutide demonstrated improvements in Alzheimer’s-related biomarkers, these did not translate into a measurable delay in disease progression. The treatment maintained a safe profile consistent with previous studies on semaglutide.
Ongoing Need for Alzheimer’s Treatments
Martin Holst Lange, Novo Nordisk’s Chief Scientific Officer, expressed gratitude to trial participants and highlighted the importance of exploring semaglutide’s potential for Alzheimer’s. He noted the ongoing challenges in treating this progressive disease, which represents a significant unmet need.
Alzheimer’s disease accounts for 60-80% of all dementia cases globally and involves a gradual worsening of symptoms that complicate daily life. The pursuit of new treatment options remains critical in addressing the societal burden associated with this condition.
Future Steps and Presentations
The one-year extension period of the evoke and evoke+ trials will be discontinued based on the current findings. Topline results will be shared at the Clinical Trials in Alzheimer’s Disease (CTAD) conference on December 3, 2025, with extended results anticipated at the Alzheimer’s and Parkinson’s Diseases Conferences in March 2026.
About Semaglutide
Semaglutide, a GLP-1 receptor agonist, is currently used for managing type 2 diabetes, chronic weight management, and related conditions. It is marketed under various brand names including Ozempic®, Rybelsus®, and Wegovy®.
About Novo Nordisk
Novo Nordisk, founded in 1923, is a global leader in healthcare and is headquartered in Denmark. The company focuses on combating serious chronic diseases, primarily through scientific innovation and expanding access to medications.
